EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

A Phase I/ IB , Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma

Roberto Pili iD, David I Quinn, Nabil Adra iD, Theodore Logan, Sean Colligan, Heather N Burney, Noah M Hahn

Cancer Medicine · 2025-04 · 14 (7)

DOI: 10.1002/cam4.70725 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Medicine, online erschienen am 27.03.2025. Verfasst von Roberto Pili und 6 weiteren Autor:innen. Beteiligte Einrichtung: University at Buffalo, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Vorinostat, Antineoplastic Combined Chemotherapy Protocols, Kidney Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunosuppressive factors such as regulatory T cells and myeloid‐derived suppressive cells (MDSCs) limit the efficacy of immunotherapies. Histone deacetylase (HDAC) inhibitors have been shown to have immunomodulatory effects. Thus, we conducted a Phase Ib clinical study with the HDAC inhibitor vorinostat and the PD‐1 inhibitor pembrolizumab in patients (pts) with metastatic urothelial (UC), renal (RCC) and prostate (PCA) carcinoma.

Methods

The phase I portion consisted of two dose levels of vorinostat (100 and 200 mg, PO daily 2 weeks ON and 1 week OFF) and a fixed dose of pembrolizumab (200 mg IV every 21 days). Patients (pts) were assigned to three cohorts: Cohort A (previously treated, anti‐PD1/PD‐L1 naïve UC and RCC), Cohort B (previously treated, anti‐PD1/PD‐L1 resistant UC and RCC pts), and Cohort C (PCA pts).

Results

Dose levels 1 and 2 were completed without DLTs. We have enrolled 44 pts. (36 evaluable) in the dose expansion cohorts, and the most common resolved grade 3/4 toxicities were diarrhea, hypophosphatemia, acute kidney injury, anemia, and hypothyroidism. For Cohort A (13 pts), B (11 pts), and C (12 pts) the objective response rate was 8%, 0%, and 17%, and the median progression‐free survival was 2.9, 3.5, and 3.5 months, respectively. Four partial responses were observed, and two PCA pts. had a complete biochemical response with undetectable PSA. Persistent lower levels of peripheral CD11 + , CD14 + HLA‐DR − monocytic MDSCs were associated with clinical benefit.

Conclusion

The combination of vorinostat and pembrolizumab is relatively well tolerated and may be active in a subset of immune checkpoint‐resistant UC/RCC pts. and immune checkpoint‐naïve PCA pts. Trial Registration: NCT02619253

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedVorinostatAntineoplastic Combined Chemotherapy ProtocolsKidney NeoplasmsProstatic NeoplasmsUrologic NeoplasmsHumansMaleAgedMiddle AgedFemaleHistone Deacetylase InhibitorsAged, 80 and overAdult

Stichwörter der Autor:innen

PD‐1 inhibitorgenitourinary malignancieshistone deacetylase inhibitor

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabVorinostatHistone Deacetylase Inhibitors

Autor:innen und Institutionen

  • University at Buffalo, Buffalo, New York, USA.
  • USC Norris Comprehensive Cancer Center, Los Angeles, California, USA.
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA.
  • Indiana University Department of Biostatistics and Health Data Science, Indianapolis, Indiana, USA.
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA.

ORCID-Profile: Roberto Pili, Nabil Adra

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Pili, R., Quinn, D. I., Adra, N., Logan, T., Colligan, S., Burney, H. N., & Hahn, N. M. (2025). A Phase I/ IB , Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma. Cancer Medicine, 14(7). https://doi.org/10.1002/cam4.70725

Vancouver

Pili R, Quinn DI, Adra N, Logan T, Colligan S, Burney HN, et al. A Phase I/ IB , Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma. Cancer Medicine. 2025;14(7). doi:10.1002/cam4.70725

BibTeX
@article{Pili2025,
  author = {Pili, Roberto and Quinn, David I and Adra, Nabil and Logan, Theodore and Colligan, Sean and Burney, Heather N and Hahn, Noah M},
  title = {A Phase I/ IB , Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {7},
  doi = {10.1002/cam4.70725}
}
Kostenlos starten →